Lisata Therapeutics wins US method-of-use patent for certepetide in pancreatic cancer, solid tumors
LSTA•Lisata Therapeutics won a US method-of-use patent for certepetide covering combination treatment of pancreatic cancer and other solid tumors; the patent expires in May 2041, while management said it supports market exclusivity into November 2043.
1. Patent coverage
The patent covers combination treatment with certepetide for pancreatic cancer and other solid tumors. It expires in May 2041, and management said the grant supports market exclusivity into November 2043.
